Corporate overview highlights pipeline progress and liquidity
AbCellera highlighted ABCL635 Phase 2 week-4 top-line readout dated Aug. 10, 2026, supporting advancement to late-stage development for menopausal VMS.
ABCL575 Phase 1 dosing completed; top-line data expected in Q4 2026, with out-licensing options under evaluation.
ABCL688 and ABCL386 progressing through IND-enabling activities; plans include IND submissions and Phase 1/2 initiation in 2027.
Liquidity position cited at more than $565 million in cash and marketable securities, with about $110 million in available government funding.
ABCL•
